Liquidia Technologies

Yahoo Finance • 15 days ago

Liquidia targets at least $1B net revenue in 2027 as YUTREPIA Q1 net product sales rise 44% sequentially

Earnings Call Insights: Liquidia (LQDA) Q1 2026 MANAGEMENT VIEW * "Three full quarters into the commercial launch of YUTREPIA, I would summarize the state of our business with 3 main points" (CEO & Director Roger Jeffs). "YUTREPIA is n... Full story

Yahoo Finance • 15 days ago

Liquidia Q1 Earnings Call Highlights

Liquidia logo MarketBeat Week in Review: 12/25 - 12/29 Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial h... Full story

Yahoo Finance • 15 days ago

Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat

medical research 16 ©Rawpixel Liquidia Corporation (NASDAQ:LQDA) shares gained nearly 3% in premarket trading on Monday after the biopharmaceutical company reported first-quarter results that exceeded analyst expectations on both earnings... Full story

Yahoo Finance • 17 days ago

This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth

On May 8, 2026, JW Asset Management reported selling 83,600 shares of Liquidia Corporation(NASDAQ:LQDA), an estimated $3.10 million trade based on quarterly average pricing. What happened According to an SEC filing dated May 8, 2026, JW... Full story

Yahoo Finance • last month

Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million

Roger Jeffs, Chief Executive Officer of Liquidia, disclosed the indirect sale of 53,300 shares of common stock through Serendipity BioPharma LLC, generating approximately $2.14 million in proceeds, according to an SEC Form 4 filing. Trans... Full story

Yahoo Finance • 2 months ago

Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s Why

Liquidia Corporation (NASDAQ:LQDA) is one of the best high growth healthcare stocks to buy now. Wells Fargo raised the price target on Liquidia Corporation (NASDAQ:LQDA) to $51 from $44 on March 23, reiterating an Overweight rating on the... Full story

Yahoo Finance • 2 months ago

The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M

Liquidia(NASDAQ:LQDA) Chief Commercial Officer Scott Moomaw reported the exercise and immediate sale of 80,000 shares of common stock, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 80,000 Transac... Full story

Yahoo Finance • 2 months ago

Mid-Cap healthcare stocks ranked by quant ratings after earnings season

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of co... Full story

Yahoo Finance • 2 months ago

Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart

On February 17, 2026, Findell Capital Management disclosed a buy of 32,000 shares of Dave(NASDAQ:DAVE) in the fourth quarter, with the estimated transaction value at $6.88 million based on the quarterly average price. What happened Accor... Full story

Yahoo Finance • 3 months ago

United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says

United Therapeutics (UTHR) remains a "top pick" due to several near- to medium-term catalysts that c PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Liquidia GAAP EPS of $0.15 misses by $0.05, revenue of $92.02M beats by $4.53M

* Liquidia press release [https://seekingalpha.com/pr/20425170-liquidia-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides] (LQDA [https://seekingalpha.com/symbol/LQDA]): Q4 GAAP EPS of $0.15 misses by $... Full story

Yahoo Finance • 3 months ago

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February... Full story

Yahoo Finance • 3 months ago

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing

Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated... Full story

Yahoo Finance • 3 months ago

Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside. On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estima... Full story

Yahoo Finance • 3 months ago

Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling

Arquitos Capital Partners, an investment management firm, released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Arquitos Capital Management reported a standout year in which the fund returned 82.1% net of fees... Full story

Yahoo Finance • 5 months ago

Arquitos Capital Management’s Updates on Liquidia Corporation (LQDA)

Arquitos Capital Management, an investment management firm, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the third quarter, the fund delivered a net return of 29.6% bringing year-to-d... Full story

Yahoo Finance • 6 months ago

This Small-Cap Consumer Stock Has Landed New Institutional Backing as Shares Surge 60%

Key Points New York City-based Findell Capital Management added 90,000 shares of Turning Point Brands for an estimated $8.9 million in the third quarter. The move marked a new position for Findell, which reported holding no shares of Turn... Full story

Yahoo Finance • 7 months ago

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of t... Full story

Yahoo Finance • 7 months ago

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to... Full story

Yahoo Finance • 7 months ago

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its... Full story